查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1864559

性行为感染传染病诊断市场按诊断测试类型、病原体类型、最终用户类型、检体类型、技术类型和产品类型划分－2025年至2032年全球预测

Sexually Transmitted Disease Diagnostics Market by Diagnostic Test Types, Pathogen Types, End-User Types, Sample Types, Technology Types, Product Types - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，性行为感染传染病诊断市场将成长至 1,821.1 亿美元，复合年增长率为 6.19%。

关键市场统计数据
基准年 2024 1125.6亿美元
预计年份：2025年 1194.2亿美元
预测年份 2032 1821.1亿美元
复合年增长率 (%) 6.19%

本文简要概述了技术创新、分散式医疗服务和不断变化的临床重点如何重塑临床环境和公共卫生领域的性行为感染诊断。

性行为感染感染的诊断领域正经历快速的技术和营运变革，这影响着诊断服务提供者、实验室网路、临床医生和公共卫生机构。分子技术、携带式检测平台和整合诊断工作流程的进步正在重塑感染疾病的检测方式、结果的沟通方式以及诊疗路径的建构方式。同时，强调分散式检查和患者自主性的不断发展的诊疗模式，推动了对就地检验和自测方案的需求，进而促使采购、品质保证和监管重点发生转变。

临床医生和公共卫生领导者正在应对不断变化的病原体情况、不断扩大的多重诊断覆盖范围，以及对快速、可操作结果以支持治疗和接触者追踪的需求。诊断试剂生产商必须应对复杂的检体类型，包括血液、各种拭子和尿液，每种样本都有不同的分析前和分析要求。同时，实验室服务正在将自动化、次世代定序和先进的免疫检测整合到其工作流程中，以提高通量和诊断准确性。本导言（构成执行摘要的其余部分）概述了推动创新的相互关联的因素、影响技术应用的营运压力，以及领导者为保持竞争力和临床相关性而必须应对的策略挑战。

分子生物学、微流体和分散式医疗保健模式的创新正在融合，从根本上改变性行为感染传染病 (STD) 的诊断和监测实践。

性行为感染感染的诊断格局正经历一场变革，这主要得益于分子技术的突破、快速便携式检测方法的成熟以及先进生物资讯学方法的整合。新兴的基于 CRISPR 的诊断技术以及核酸扩增技术的进步，包括 PCR 和次世代定序，正在提高对更多病原体的检测灵敏度和特异性。同时，微流体实验室晶片解决方案和改进的免疫检测方法（例如，增强型侧向流动检测）正在实现真正的即时检测流程，从而在传统实验室之外也能提供可靠的检测结果。

这些技术进步与医疗服务模式的变革相吻合。居家检测模式和直接面向消费者的通路的扩展，在提升病患就医便利性的同时，也为结果解读、确诊检测和照护协调带来了新的挑战。为此，诊断实验室正在采用自动化和多重检测平台，以实现高通量筛检和全面的病原体检测。公共卫生机构正在利用可互通的数据系统和基因组监测，加强对疫情爆发和抗药性模式的监测，凸显了将诊断结果与流行病学资讯结合的重要性日益凸显。这些变化共同重塑了整个诊断生态系统的竞争优势、监管重点和伙伴关係模式。

评估2025年美国关税调整对性传染病诊断相关人员的供应链和采购的实际影响

2025年美国关税政策对诊断供应链和采购管道产生了实际的营运和策略影响。进口设备、试剂和特殊组件的关税调整增加了许多供应商的到岸成本，迫使製造商和经销商重新评估筹资策略、库存管理政策和定价模式。为此，一些企业加快了本土化生产，实现了供应链多元化，并探索了其他组件供应商，以期维持利润率并按时交付。

关税引发的成本变化正在影响资本设备和耗材的采购决策，并波及临床和公共卫生领域。实验室和医院正优先考虑总体拥有成本分析以及整合检测项目的平台，以降低单位成本。同时，试剂和套件供应商正在修订分销协议，并探索区域製造合作伙伴关係，以减轻关税影响带来的复杂性和风险。因此，各方更重视加强供应链韧性、发展策略供应商关係，并采取兼顾成本控制、维持诊断品质和保障患者照护连续性的采购方式。

透过对诊断方式、病原体标靶、终端用户环境、检体要求、平台技术和产品类型进行深度细分，提供可操作的市场洞察。

细分市场分析揭示了不同诊断方法、病原体标靶、终端用户环境、检体类型、技术平台和产品形式所带来的需求差异和技术适用性。基于诊断测试类型，传统检测仍然是高通量生物标记、血液和尿液检查工作流程的核心，而分子检测（例如次世代定序、核酸增幅检查和聚合酵素链锁反应）则为复杂病原体的检测提供了黄金标准灵敏度。可携式分析仪、快速诊断测试和自我测试检测套组等照护现场形式正在扩大检测范围，但需要进行严格的检验，以确保其准确性与实验室方法相当。

依病原体划分，可以发现针对不同病原体的临床和商业需求各有重点：细菌感染疾病（如披衣菌感染、淋病和梅毒）；病毒感染疾病（如B型肝炎、单纯疱疹、HIV 和 HPV）；寄生虫感染疾病（如滴虫病）；以及商业性感染疾病（如念珠菌症）。按最终用户划分，诊断实验室（包括病理实验室和研究机构）优先考虑检测通量和多重检测能力，而面向消费者的直接检测和透过线上药局提供的居家照护管道则强调易用性和清晰的后续指导。医院和诊所需要快速报告检测结果并将其整合到电子健康记录中，而公共卫生部门则需要强大的报告功能和监测系统互通性。

检体类型细分突出了血液来源的血浆和血清、生殖器、口腔和直肠拭子检体以及尿液检体（包括初段尿和中段尿）各自独特的检体製备管理和套件设计考虑。技术细分突出了基于 CRISPR 的诊断方法、免疫检测（如 ELISA 和侧向层析）、实验室晶片微流体技术以及光谱技术（如红外光谱和拉曼光谱）在辅助分析中日益增长的重要性。产品类型细分区分了耗材（如移液器和试管）、设备（如分析仪和自动化系统）以及用于细菌和病毒诊断的试剂和试剂套件，每种产品都有不同的采购週期和监管途径。这些相互交织的细分层级有助于制定市场推广策略、临床检验重点和产品开发蓝图。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和基础设施因素如何影响诊断方法的采用、取得和伙伴关係模式

区域趋势正在影响美洲、欧洲、中东、非洲和亚太地区的需求模式、监管要求和伙伴关係机会。在美洲，临床网路和公共卫生机构正在部署集中式检测平台并扩大社区检测范围，以解决在获取医疗服务和快速诊断方面持续存在的差距。同时，保险覆盖政策和不断变化的报销框架正在影响新型分子诊断和照护现场方案的普及速度。

在欧洲、中东和非洲地区，不同的管理体制和实验室基础设施导致高复杂度检测和分散式快速检测的普及程度存在差异。该地区的公共卫生重点在于监测、抗菌素抗药性监测和公平获取医疗服务，因此需要性能可靠、成本低廉且具有高现场应用价值的诊断技术。在亚太地区，强大的生产能力、庞大且多元化的患者群体以及数位化医疗的快速普及，都促进了整合诊断平台的加速应用以及试剂和耗材的在地化生产。总而言之，这些区域特征决定了打入市场策略、经销伙伴以及服务和支援能力的本地化，以满足特定的临床和监管要求。

结合平台整合、监管覆盖和创新技术合作，采取竞争与合作并重的企业策略，以确立在性传染病诊断领域的领先地位。

主要企业层面洞察聚焦于策略定位、产品组合广度和能力，这些因素共同促成了企业在竞争激烈的诊断生态系统中的差异化。领先的仪器製造商优先考虑平台集成，提供支援多重检测并可与实验室资讯系统集成的分析仪和自动化系统。试剂和套件供应商专注于针对细菌和病毒诊断的检验病原体特异性检测方法，同时投资于供应链的稳健性和多司法管辖区的监管註册。新兴企业优先考虑颠覆性技术，例如基于 CRISPR 的检测方法、实验室晶片微流体技术和新型光谱学方法，并寻求临床检验伙伴关係和有针对性的试点部署以建立信誉。

通路和服务模式正日益成为重要的差异化因素。能够提供灵活采购方案、培训和技术支援以及便于向公共卫生机构报告的资料管理服务的公司，往往更容易获得医疗机构的青睐。同时，那些为消费者产品建立清晰推广路径（包括支援确诊检测和医疗合作）的公司，则更有利于抓住家庭检测管道的需求。成熟製造商与创新Start-Ups之间的策略合作，例如共同开发和分销协议，有助于将新型诊断技术快速转化为可扩展的产品，同时降低技术和监管风险。

为製造商、实验室和公共卫生合作伙伴提供切实可行的策略重点，以加速诊断技术的普及应用，并建立一个具有韧性的诊断体系。

产业领导者应抓住新机会，推动一系列协作行动，协调产品开发、监管策略、供应链韧性和商业模式。优先投资于兼具实验室级性能和分散式环境实用性的技术，从而实现平台在医院、社区诊所和消费者场所的部署，同时保持临床可靠性。同时，应制定清晰的循证计划，重点关注实际应用效能、验证性检测途径和成本效益，以支持支付方和采购决策。

我们将进一步实现供应商多元化，并在条件允许的情况下将零件采购转移到近岸地区，以降低关税波动风险，并提高应对力。我们将制定分层市场推广策略，针对诊断实验室、医院、公共卫生部门和居家照护管道优化通讯和支持，提供包括培训、整合协助和数据报告在内的捆绑式服务。最后，我们将与公共卫生组织、学术机构和技术创新者建立策略合作伙伴关係，以加速检验研究并扩大监测应用，从而增强临床信心，并为长期应用奠定基础。

严谨的混合方法研究过程（结合从业者访谈、技术文献回顾和交叉检验的分析框架）确保了诊断结果的可靠性。

本报告的调查方法结合了第一手资料和第二手资料，旨在全面了解性行为感染）诊断的现状。第一手资料包括与临床实验室主任、感染疾病专家、公共卫生负责人和诊断行业高管进行结构化访谈和对话，以了解当前的实践、推广障碍和战略重点。这些第一手资料促成了对临床和消费者管道的技术准备、营运限制和推广驱动因素的定性评估。

二次研究回顾了同侪审查文献、监管指导文件、会议报告和产品技术规范，以检验技术描述、检体处理要求和监管路径。对一级研究和二次研究进行交叉检验，确保结论既反映了实务经验，也体现了技术证据。分析架构着重于技术成熟度、临床效用、供应链因素和商业化动态。尽可能地，对来自多个资讯来源的证据进行三角验证，以减少偏差并增强本报告结论的可信度。

全面分析创新、业务连续性和策略合作如何决定哪些诊断产品能够获得临床应用并创造公共卫生价值。

总之，性行为感染传染病诊断正处于转折点。技术进步、不断演进的诊疗模式以及供应链现状正在相互交织，重新定义临床工作流程和市场机会。分子检测、基于 CRISPR 的平台、微流体技术和先进免疫检测的创新，正在拓展中心实验室和分散式检查环境的能力。因此，相关人员必须权衡快速灵敏诊断的前景与检验、监管合规以及融入诊疗路径等实际挑战。

那些积极主动地将产品开发与终端用户需求相结合、加强供应链以应对关税和采购衝击、并建立连接临床、公共卫生和消费者环境的伙伴关係关係的领导者，将更有能力将技术的潜力转化为持续的临床成果。本摘要中提出的建议为指导投资、合作和营运决策提供了策略基础，这些决策将塑造性行为感染检测和管理的未来。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将快速照护现场分子检测整合到社区医疗保健机构中，以缩短诊断时间
  • 开发用于同时检测多种性行为感染传染病（包括新出现的病原体）的多重检测平台
  • 为高风险族群引入用于分散性行为感染传染病筛检的自采集和居家检体采集试剂套件
  • 引入人工智慧驱动的数据分析，建构性行为感染传染病爆发预测模型，并制定个人化治疗策略
  • 扩大基于 CRISPR 的诊断技术在披衣菌感染和淋病高灵敏度和特异性检测的应用
  • 透过远端医疗提供者和诊断试剂生产商之间的合作，扩大远距性行为感染检测的覆盖范围。
  • 重点研究抗药性检测方法，以指导抗药性感染疾病的标靶治疗

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章性行为感染传染病诊断市场（依诊断检验类型划分）

  • 实验室检测
    • 基于生物标记的检测
    • 血液检查
    • 尿液检查
  • 分子检测
    • 次世代定序
    • 核酸增幅检查（NAATs）
    • 聚合酵素链锁反应（PCR）
  • 就地检验
    • 携带式分析仪
    • 快速诊断测试
    • 自测检测套组

第九章 依病原体类型性行为感染传染病诊断市场

  • 细菌性行为感染传染病
    • 披衣菌感染
    • 淋病
    • 梅毒
  • 霉菌性性行为感染感染
    • 念珠菌症
  • 寄生性行为感染传染病
    • 滴虫病
  • 病毒性行为感染传染病
    • B型肝炎
    • 单纯疱疹病毒
    • 人类免疫力缺乏病毒（HIV）
    • 人类乳突病毒（HPV）

第十章 以最终使用者类型分類的性行为感染传染病诊断市场

  • 诊断实验室
    • 病理实验室
    • 研究所
  • 居家医疗环境
    • 直接面向消费者的测试
    • 网路药房
  • 医院和诊所
    • 医疗设施
    • 门诊部
  • 公共卫生部门
    • 社区医疗中心
    • 州卫生部门

第十一章 依检体类型分類的性行为感染传染病诊断市场

  • 血液样本
    • 电浆
    • 血清
  • 拭子检体
    • 生殖器拭子
    • 口腔拭子
    • 直肠拭子
  • 尿液检体
    • 第一次尿液
    • 中段尿

第十二章 依技术类型性行为感染传染病诊断市场

  • 基于CRISPR的诊断
    • CRISPR-Cas
  • 免疫检测
    • ELISA
    • 横向流动化验
  • 微流体技术
    • 晶片实验室
  • 光谱学
    • 红外线的
    • 拉曼光谱

第十三章性行为感染传染病诊断市场（依产品类型划分）

  • 消耗品
    • 移液器
    • 管子
  • 装置
    • 分析器
    • 自动化系统
  • 试剂和套件
    • 细菌性行为感染传染病检测套件
    • 病毒性性性行为感染检测套件

第十四章 各地区性行为感染传染病诊断市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章性行为感染传染病诊断市场（依群体划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国性行为感染传染病诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Abbott Laboratories
    • Astra Biotech Gmbh
    • Becton Dickinson and company
    • Bio-Rad Laboratories, Inc.
    • bioMerieux SA
    • Danaher Corporation
    • Daye Limited
    • Diasorin SpA
    • F. Hoffmann-La Roche Ltd
    • Geneproof
    • Hologic Inc.
    • Jiangsu BioPerfectus Technologies Co., Ltd
    • Liferiver Bio-Tech Corp.
    • MedMira Inc
    • Meridian Bioscience Inc.
    • Mylab Discovery Solutions Pvt. Ltd.
    • OraSure Technologies, Inc.
    • Qiagen Inc
    • Quest Consumer Inc.
    • Sansure Biotech Inc.
    • Seegene Inc.
    • Siemens Healthcare GmbH
    • Thermo Fisher Scientific, Inc.
Product Code: MRR-6D54EA0F9447

The Sexually Transmitted Disease Diagnostics Market is projected to grow by USD 182.11 billion at a CAGR of 6.19% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 112.56 billion
Estimated Year [2025] USD 119.42 billion
Forecast Year [2032] USD 182.11 billion
CAGR (%) 6.19%

A concise orientation to how technological innovation, decentralized care delivery, and changing clinical priorities are reshaping STD diagnostics across clinical and public health settings

The sexually transmitted disease diagnostics landscape is undergoing rapid technical and operational shifts that affect diagnostics providers, laboratory networks, clinical practitioners, and public health entities. Advances in molecular technologies, portable testing platforms, and integrated diagnostics workflows are reshaping how infections are detected, how results are delivered, and how care pathways are constructed. Meanwhile, evolving care models that emphasize decentralized testing and greater patient autonomy are increasing demand for point-of-care and self-testing options, which in turn changes procurement, quality assurance, and regulatory priorities.

Clinicians and public health leaders are adapting to changes in pathogen prevalence, the expanding scope of multiplex diagnostics, and the need for faster, actionable results to support treatment and contact tracing. Diagnostic manufacturers must navigate a complex array of sample types, including blood, various swabs, and urine, each with distinct pre-analytic and analytic requirements. At the same time, laboratory services are integrating automation, next-generation sequencing, and advanced immunoassays into workflows to improve throughput and diagnostic certainty. This introduction frames the remainder of the executive summary by outlining the intersecting drivers of innovation, the operational pressures shaping adoption, and the strategic questions leaders must address to remain competitive and clinically relevant.

How converging innovations in molecular biology, microfluidics, and decentralized care models are fundamentally altering STD diagnostics and surveillance practices

The landscape for sexually transmitted disease diagnostics is shifting in transformative ways, driven by breakthroughs in molecular techniques, the maturation of rapid and portable testing, and the incorporation of advanced bioinformatic methods. Emerging CRISPR-based diagnostics and improvements in nucleic acid amplification, including PCR and next-generation sequencing, are increasing sensitivity and specificity across a wider range of pathogens. Concurrently, microfluidic lab-on-a-chip solutions and refined immunoassays such as enhanced lateral flow formats are enabling true point-of-care workflows that deliver reliable results outside traditional laboratories.

These technical advances coincide with changes in care delivery. Home-based testing models and direct-to-consumer distribution channels are expanding patient access while introducing new considerations around result interpretation, confirmatory testing, and linkage to care. Diagnostic laboratories are responding by adopting automation and multiplex platforms that support high-throughput screening and comprehensive pathogen panels. Public health entities are leveraging interoperable data systems and genomic surveillance to monitor outbreaks and resistance patterns, which underscores the growing importance of integrating diagnostic outputs with epidemiologic intelligence. Together, these shifts are redefining competitive advantage, regulatory priorities, and partnership models across the diagnostics ecosystem.

Evaluating the practical supply chain and procurement consequences of the United States tariff adjustments enacted in 2025 on STD diagnostics stakeholders

United States tariff policies enacted in 2025 have introduced tangible operational and strategic implications across diagnostic supply chains and procurement channels. Tariff adjustments on imported instruments, reagents, and specialized components have increased landed costs for many suppliers, prompting manufacturers and distributors to reassess sourcing strategies, inventory policies, and pricing models. In response, several organizations have accelerated onshoring initiatives, diversified supplier bases, and explored alternative component suppliers to preserve margin and maintain delivery timelines.

These tariff-induced cost dynamics ripple through clinical and public health settings by influencing purchasing decisions for capital equipment and recurring consumables. Laboratories and hospitals are prioritizing total cost of ownership analyses and prioritizing platforms that consolidate test menus to reduce unit costs. Meanwhile, reagent and kit providers are re-evaluating distribution agreements and exploring regional manufacturing partnerships to mitigate customs complexity and tariff exposure. The net effect is a renewed emphasis on supply chain resilience, strategic supplier relationships, and procurement practices that balance cost containment with the imperative of maintaining diagnostic quality and continuity of patient care.

Deep segmentation intelligence that connects diagnostic modalities, pathogen targets, end-user settings, sample requirements, platform technologies, and product categories into actionable market implications

Segmentation insights reveal differentiated demand drivers and technology fit across diagnostic modalities, pathogen targets, end-user settings, sample types, technology platforms, and product forms. Based on diagnostic test types, laboratory tests remain central for high-throughput biomarker-based, blood, and urine testing workflows, while molecular tests such as next-generation sequencing, nucleic acid amplification tests, and polymerase chain reaction deliver gold-standard sensitivity for complex pathogen detection. Point-of-care formats including portable analyzers, rapid diagnostic tests, and self-test kits are expanding access but require careful validation to ensure parity with laboratory methods.

Pathogen-focused segmentation identifies distinct clinical and commercial priorities across bacterial infections like chlamydia, gonorrhea, and syphilis; viral infections including hepatitis B, herpes simplex, HIV, and HPV; parasitic causes such as trichomoniasis; and fungal conditions like candidiasis. End-user segmentation highlights that diagnostic laboratories, including pathology and research labs, prioritize throughput and multiplex capability, whereas home care channels, through direct-to-consumer testing and online pharmacies, emphasize ease of use and clear guidance for follow-up. Hospitals and clinics balance rapid turnaround with integration into electronic medical records, and public health departments require robust reporting and surveillance interoperability.

Sample-type segmentation underscores that blood-derived plasma and serum, swab collections from genital, oral, and rectal sites, and urine samples including first-catch and midstream variants each impose unique pre-analytic controls and kit design considerations. Technology segmentation shows the growing relevance of CRISPR-based diagnostics, immunoassays such as ELISA and lateral flow, lab-on-a-chip microfluidics, and spectroscopy techniques including infrared and Raman for adjunctive analysis. Product-type segmentation differentiates consumables like pipettes and tubes, instruments such as analyzers and automation systems, and reagents and kits tailored for bacterial versus viral diagnostics, each with distinct procurement cycles and regulatory pathways. These intersecting segmentation layers inform go-to-market strategies, clinical validation priorities, and product development roadmaps.

Regional dynamics and infrastructure considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence diagnostic adoption, access, and partnership models

Regional dynamics shape demand patterns, regulatory imperatives, and partnership opportunities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas region, clinical networks and public health agencies are deploying a mix of centralized laboratory platforms and expanding community-based testing to address persistent gaps in access and timely diagnosis. Meanwhile, coverage policies and evolving reimbursement frameworks influence the adoption cadence for novel molecular and point-of-care solutions.

Across Europe, Middle East & Africa, heterogeneous regulatory regimes and varying laboratory infrastructure drive differential adoption of high-complexity assays versus decentralized rapid tests. Public health priorities in this region emphasize surveillance, antimicrobial resistance monitoring, and equitable access, which creates demand for robust, low-cost diagnostics with strong field performance. In the Asia-Pacific region, manufacturing capacity, a large and diverse patient base, and rapid uptake of digital health integrations support accelerated adoption of integrated diagnostic platforms and localized production of reagents and consumables. Collectively, these regional characteristics inform market entry strategies, distribution partnerships, and the localization of service and support capabilities to meet specific clinical and regulatory requirements.

Competitive and collaborative company strategies that combine platform consolidation, regulatory reach, and innovative tech partnerships to win in STD diagnostics

Key company-level insights focus on strategic positioning, portfolio breadth, and capabilities that enable differentiation in a competitive diagnostics ecosystem. Leading instrument manufacturers emphasize platform consolidation, providing analyzers and automation systems that support multiplex testing and integrate with laboratory information systems. Reagent and kit providers focus on validated, pathogen-specific assays for bacterial and viral diagnostics while investing in supply chain robustness and regulatory registrations across multiple jurisdictions. Emerging players prioritize disruptive technologies such as CRISPR-based assays, lab-on-a-chip microfluidics, and novel spectroscopy approaches, seeking clinical validation partnerships and targeted pilot deployments to build credibility.

Channel and service models are increasingly important differentiators. Companies that offer flexible procurement options, training and technical support, and data-management services that facilitate reporting to public health authorities tend to achieve higher adoption in institutional settings. At the same time, organizations that develop clear pathways for consumer-facing products, including support for confirmatory testing and linkage to care, are better positioned to capture demand in home testing channels. Strategic collaborations between established manufacturers and innovative startups, including co-development and distribution agreements, are accelerating the translation of novel diagnostics into scalable offerings while mitigating technical and regulatory risk.

Practical and actionable strategic priorities for manufacturers, laboratories, and public health partners to accelerate adoption and build resilient diagnostic businesses

Industry leaders should pursue a set of coordinated actions that align product development, regulatory strategy, supply chain resilience, and commercial models to capture emerging opportunities. Prioritize investments in technologies that bridge laboratory-grade performance with decentralized usability so that platforms can be deployed across hospitals, community clinics, and consumer settings while maintaining clinical integrity. Simultaneously, establish clear evidence-generation plans that emphasize real-world performance, confirmatory pathways, and cost-effectiveness to support payer and procurement decisions.

Strengthening supplier diversity and nearshoring components where feasible will reduce exposure to tariff volatility and improve responsiveness to demand surges. Develop tiered go-to-market approaches that tailor messaging and support to diagnostic laboratories, hospitals, public health departments, and home care channels, and create bundled service offerings that include training, integration support, and data reporting capabilities. Finally, pursue strategic partnerships with public health agencies, academic centers, and technology innovators to accelerate validation studies and expand surveillance applications, thereby reinforcing clinical credibility and creating pathways to long-term adoption.

A rigorous mixed-methods research process combining practitioner interviews, technical literature review, and cross-validated analytical frameworks to ensure robust diagnostic insights

The research methodology for this report combined primary and secondary approaches to develop a comprehensive view of the sexually transmitted disease diagnostics landscape. Primary research included structured interviews and consultations with clinical laboratory directors, infectious disease clinicians, public health officials, and diagnostic industry executives to capture current practices, barriers to adoption, and strategic priorities. These firsthand perspectives informed qualitative assessments of technology readiness, operational constraints, and adoption drivers across clinical and consumer channels.

Secondary research reviewed peer-reviewed literature, regulatory guidance documents, conference proceedings, and product technical specifications to validate technology descriptions, sample handling requirements, and regulatory pathways. Cross-validation between primary and secondary inputs ensured that conclusions reflect both practitioner experience and the technical evidence base. Analytical frameworks emphasized technology maturity, clinical utility, supply chain factors, and commercialization dynamics. Wherever possible, evidence was triangulated across multiple sources to reduce bias and increase the robustness of insights included in the report.

Summative perspectives on how innovation, operational resilience, and strategic collaboration will determine which diagnostic offerings gain clinical traction and public health value

In conclusion, sexually transmitted disease diagnostics are at an inflection point where technological advances, evolving care models, and supply chain realities intersect to redefine clinical workflows and market opportunities. Innovations in molecular testing, CRISPR-based platforms, microfluidics, and enhanced immunoassays are expanding the capabilities of both centralized laboratories and decentralized testing environments. As a result, stakeholders must balance the promise of rapid, sensitive diagnostics with the practicalities of validation, regulatory compliance, and integration into care pathways.

Leaders who proactively align product development with end-user needs, fortify supply chains against tariff and sourcing shocks, and create partnerships that bridge clinical, public health, and consumer contexts will be best positioned to translate technological promise into sustained clinical impact. The actions recommended in this summary provide a strategic foundation to guide investment, collaboration, and operational decisions that will shape the future of STD detection and management.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of rapid point-of-care molecular assays in community health settings to reduce time to diagnosis
  • 5.2. Development of multiplexed testing platforms for simultaneous detection of multiple STDs including emerging pathogens
  • 5.3. Adoption of self-collection and at-home sampling kits for decentralized STD screening in high-risk populations
  • 5.4. Implementation of AI-driven data analytics for predictive modeling of STD outbreaks and personalized treatment strategies
  • 5.5. Increasing use of CRISPR-based diagnostics for highly sensitive and specific detection of chlamydia and gonorrhea
  • 5.6. Collaboration between telemedicine providers and diagnostic manufacturers to expand remote STD testing access
  • 5.7. Focus on antibiotic resistance detection assays to guide targeted therapy for drug-resistant gonorrhea infections

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Sexually Transmitted Disease Diagnostics Market, by Diagnostic Test Types

  • 8.1. Laboratory Tests
    • 8.1.1. Biomarker-Based Tests
    • 8.1.2. Blood Tests
    • 8.1.3. Urine Tests
  • 8.2. Molecular Tests
    • 8.2.1. Next-Generation Sequencing
    • 8.2.2. Nucleic Acid Amplification Tests (NAATs)
    • 8.2.3. Polymerase Chain Reaction (PCR)
  • 8.3. Point-of-Care Tests
    • 8.3.1. Portable Analyzers
    • 8.3.2. Rapid Diagnostic Tests
    • 8.3.3. Self-Test Kits

9. Sexually Transmitted Disease Diagnostics Market, by Pathogen Types

  • 9.1. Bacterial STDs
    • 9.1.1. Chlamydia
    • 9.1.2. Gonorrhea
    • 9.1.3. Syphilis
  • 9.2. Fungal STDs
    • 9.2.1. Candidiasis
  • 9.3. Parasitic STDs
    • 9.3.1. Trichomoniasis
  • 9.4. Viral STDs
    • 9.4.1. Hepatitis B
    • 9.4.2. Herpes Simplex Virus
    • 9.4.3. Human Immunodeficiency Virus (HIV)
    • 9.4.4. Human Papillomavirus (HPV)

10. Sexually Transmitted Disease Diagnostics Market, by End-User Types

  • 10.1. Diagnostic Laboratories
    • 10.1.1. Pathology Laboratories
    • 10.1.2. Research Laboratories
  • 10.2. Home Care Settings
    • 10.2.1. Direct-to-Consumer Testing
    • 10.2.2. Online Pharmacies
  • 10.3. Hospitals and Clinics
    • 10.3.1. Healthcare Facilities
    • 10.3.2. Outpatient Clinics
  • 10.4. Public Health Departments
    • 10.4.1. Community Health Centers
    • 10.4.2. State Health Departments

11. Sexually Transmitted Disease Diagnostics Market, by Sample Types

  • 11.1. Blood Samples
    • 11.1.1. Plasma
    • 11.1.2. Serum
  • 11.2. Swab Samples
    • 11.2.1. Genital Swabs
    • 11.2.2. Oral Swabs
    • 11.2.3. Rectal Swabs
  • 11.3. Urine Samples
    • 11.3.1. First Catch
    • 11.3.2. Midstream

12. Sexually Transmitted Disease Diagnostics Market, by Technology Types

  • 12.1. CRISPR-Based Diagnostics
    • 12.1.1. CRISPR-Cas
  • 12.2. Immunoassays
    • 12.2.1. ELISA
    • 12.2.2. Lateral Flow Assays
  • 12.3. Microfluidics
    • 12.3.1. Lab-on-a-Chip
  • 12.4. Spectroscopy
    • 12.4.1. Infrared
    • 12.4.2. Raman Spectroscopy

13. Sexually Transmitted Disease Diagnostics Market, by Product Types

  • 13.1. Consumables
    • 13.1.1. Pipettes
    • 13.1.2. Tubes
  • 13.2. Instruments
    • 13.2.1. Analyzers
    • 13.2.2. Automation Systems
  • 13.3. Reagents and Kits
    • 13.3.1. Kits for Bacterial STDs
    • 13.3.2. Kits for Viral STDs

14. Sexually Transmitted Disease Diagnostics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Sexually Transmitted Disease Diagnostics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Sexually Transmitted Disease Diagnostics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Abbott Laboratories
    • 17.3.2. Astra Biotech Gmbh
    • 17.3.3. Becton Dickinson and company
    • 17.3.4. Bio-Rad Laboratories, Inc.
    • 17.3.5. bioMerieux SA
    • 17.3.6. Danaher Corporation
    • 17.3.7. Daye Limited
    • 17.3.8. Diasorin S.p.A
    • 17.3.9. F. Hoffmann-La Roche Ltd
    • 17.3.10. Geneproof
    • 17.3.11. Hologic Inc.
    • 17.3.12. Jiangsu BioPerfectus Technologies Co., Ltd
    • 17.3.13. Liferiver Bio-Tech Corp.
    • 17.3.14. MedMira Inc
    • 17.3.15. Meridian Bioscience Inc.
    • 17.3.16. Mylab Discovery Solutions Pvt. Ltd.
    • 17.3.17. OraSure Technologies, Inc.
    • 17.3.18. Qiagen Inc
    • 17.3.19. Quest Consumer Inc.
    • 17.3.20. Sansure Biotech Inc.
    • 17.3.21. Seegene Inc.
    • 17.3.22. Siemens Healthcare GmbH
    • 17.3.23. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TEST TYPES, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TEST TYPES, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPES, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPES, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER TYPES, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER TYPES, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPES, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPES, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY TYPES, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY TYPES, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPES, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPES, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TEST TYPES, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TEST TYPES, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BIOMARKER-BASED TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BIOMARKER-BASED TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BIOMARKER-BASED TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BIOMARKER-BASED TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BIOMARKER-BASED TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BIOMARKER-BASED TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY URINE TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY URINE TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY URINE TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY URINE TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY URINE TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY URINE TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS (NAATS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS (NAATS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS (NAATS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS (NAATS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS (NAATS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS (NAATS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PORTABLE ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PORTABLE ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PORTABLE ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PORTABLE ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PORTABLE ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PORTABLE ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SELF-TEST KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SELF-TEST KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SELF-TEST KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SELF-TEST KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SELF-TEST KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SELF-TEST KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPES, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPES, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL STDS, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL STDS, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL STDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL STDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL STDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL STDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL STDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL STDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL STDS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL STDS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL STDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL STDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL STDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL STDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL STDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL STDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC STDS, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC STDS, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC STDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC STDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC STDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC STDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC STDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC STDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TRICHOMONIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TRICHOMONIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TRICHOMONIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TRICHOMONIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TRICHOMONIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TRICHOMONIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL STDS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL STDS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL STDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL STDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL STDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL STDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL STDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL STDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER TYPES, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER TYPES, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOLOGY LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOLOGY LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOLOGY LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOLOGY LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOLOGY LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOLOGY LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIRECT-TO-CONSUMER TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIRECT-TO-CONSUMER TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIRECT-TO-CONSUMER TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIRECT-TO-CONSUMER TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIRECT-TO-CONSUMER TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIRECT-TO-CONSUMER TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEALTHCARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEALTHCARE FACILITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEALTHCARE FACILITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEALTHCARE FACILITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEALTHCARE FACILITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEALTHCARE FACILITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE HEALTH DEPARTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE HEALTH DEPARTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE HEALTH DEPARTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE HEALTH DEPARTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE HEALTH DEPARTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE HEALTH DEPARTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPES, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPES, 2025-20